TOKYO, Jan. 27, 2025 /PRNewswire/ — ThinkCyte, a biotechnology company pioneering novel artificial intelligence (AI)-based cell analysis and sorting instruments, announced today that it will begin the pre-commercial launch of its new cell analysis platform, VisionCyte™. The announcement coincides with the 2025 Society for Laboratory Automation and Screening (SLAS) conference in San Diego, CA from January 27-30, 2025, where VisionCyte was named a finalist for the 2025 New Product Award. The launch of VisionCyte extends ThinkCyte’s product portfolio of life science research platforms beyond VisionSort, the company’s flagship product launched in 2023 and adopted by leading biopharmaceutical companies and academic institutions worldwide.
The VisionCyte platform leverages high resolution morphological profiling, high-throughput capabilities, and advanced AI analysis to uncover novel biomarkers and facilitate the discovery of new and diversified hits and targets for drug discovery. The full commercial rollout of VisionCyte will occur in 2025, with an initial line of customer ready units available in H2 2025. The company also announced the launch of its Celluminate cell tracking kits, compatible with both VisionSort and VisionCyte, for enabling discovery applications in areas where existing cell surface cell markers are limited such as specific hematological conditions, stem cell research, and age-related diseases.
“The expansion of our product portfolio reflects our unwavering commitment to advancing life science research.” said Waichiro Katsuda, Chief Executive Officer at ThinkCyte. “By introducing innovative solutions that address the evolving needs of scientists worldwide, we’re not just adding products—we’re providing the tools to accelerate discoveries in disease understanding and drug discovery to improve lives.”
More information about the VisionCyte platform can be found by visiting the ThinkCyte booth (#2632) at SLAS 2025 or by visiting thinkcyte.com/visioncyte.
About ThinkCyte
ThinkCyte, founded in 2016 with offices in Tokyo, Japan and Redwood City, California is a biotechnology company that develops innovative scientific instruments based on integrated, multidisciplinary technologies to enable life science research, diagnostics, and therapeutic development. The company pioneered Ghost Cytometry™, a proprietary AI-based, label-free cell analysis and sorting technology and partners with major global biopharmaceutical companies and leading academic research institutes to drive pioneering research. For more information, please visit www.thinkcyte.com.
SOURCE ThinkCyte Inc.
NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation…
PARSIPPANY, N.J., April 11, 2025 /PRNewswire/ -- Diagnostica Stago, Inc., a global leader in hemostasis…
The Company Expects the Continued Sale of OPKO-Branded Products in China but is Pausing Activities…
BRIDGEWATER, N.J., April 11, 2025 /PRNewswire/ -- Hamamatsu Photonics, a global leader in whole slide…
NASHVILLE, Tenn., April 11, 2025 /PRNewswire/ -- Entering its 15th year, ProviderTrust continues to lead…
Through the Technology in Space Prize, two startups will receive more than $650,000 in total…